18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial - The Lancet

Salvage therapy for prostate cancer after radical prostatectomy

Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

Frontiers Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy?

Axumin LOCATE Trial Results Axumin® (fluciclovine F 18) Injection

Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI - ScienceDirect

Prostate Cancer: Clinical Implications From the EMPIRE-1 Trial

O papel do PET/CT com 18F-fluciclovina no prognóstico de pacientes com câncer de próstata - Oncologia Brasil

Effect of 18F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial

Clinical practice in prostate PET imaging - Sean J. Huls, Brian Burkett, Eric Ehman, Val J. Lowe, Rathan M. Subramaniam, A. Tuba Kendi, 2023

Mask R-CNN assisted 2.5D object detection pipeline of 68Ga-PSMA-11 PET/CT-positive metastatic pelvic lymph node after radical prostatectomy from solely CT imaging

PDF) Impact of 18F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy

Cancers, Free Full-Text